Regeneron Pharmaceuticals (REGN) Enterprise Value (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Enterprise Value of -$8.0 billion for Q2 2026, down 7.03% year-over-year from -$8.6 billion in Q2 2025, and up 8.67% quarter-over-quarter from -$8.8 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Enterprise Value (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$8.0 billion for Q2 2026.
- In Q2 2026, Enterprise Value fell 7.03% year-over-year to -$8.0 billion; the TTM figure through Jun 2026 stood at -$8.0 billion (down 7.03% YoY), while the FY2025 annual figure was -$8.6 billion, up 4.52% from the prior year.
- Enterprise Value for Q2 2026 stood at -$8.0 billion, up from -$8.8 billion in the prior quarter.
- The five-year high for Enterprise Value was -$7.0 billion in Q3 2022, with the low at -$10.8 billion in Q4 2023.
- The 5-year median for Enterprise Value is -$8.7 billion (2025), against an average of -$8.7 billion.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 101.23% in 2022, then gained 23.85% in 2025.
- Regeneron Pharmaceuticals' Enterprise Value stood at -$7.7 billion in 2022, then plunged by 40.07% to -$10.8 billion in 2023, then climbed by 16.9% to -$9.0 billion in 2024, then advanced by 4.52% to -$8.6 billion in 2025, then advanced by 7.1% to -$8.0 billion in 2026.
- Business Quant data shows REGN's Enterprise Value at -$8.0 billion in Q2 2026, -$8.8 billion in Q1 2026, and -$8.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.99 Bn |
| Mar 31, 2026 | -8.75 Bn |
| Dec 31, 2025 | -8.61 Bn |
| Sep 30, 2025 | -8.44 Bn |
| Jun 30, 2025 | -7.47 Bn |
| Mar 31, 2025 | -8.35 Bn |
| Dec 31, 2024 | -9.01 Bn |
| Sep 30, 2024 | -9.80 Bn |
| Jun 30, 2024 | -9.81 Bn |
| Mar 31, 2024 | -10.52 Bn |
| Dec 31, 2023 | -10.84 Bn |
| Sep 30, 2023 | -9.91 Bn |
| Jun 30, 2023 | -8.93 Bn |
| Mar 31, 2023 | -8.96 Bn |
| Dec 31, 2022 | -7.74 Bn |
| Sep 30, 2022 | -7.02 Bn |
| Jun 30, 2022 | -7.57 Bn |
| Mar 31, 2022 | -7.05 Bn |
| Dec 31, 2021 | -5.69 Bn |
| Sep 30, 2021 | -5.79 Bn |